Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Biologic therapy for atopic asthma and beyond.

Caruso M, Crisafulli E, Lizzio R, Polosa R.

Curr Opin Allergy Clin Immunol. 2013 Dec;13(6):677-85. doi: 10.1097/ACI.0000000000000012. Review.

PMID:
24152740
2.

Stratified approaches to the treatment of asthma.

Holgate ST.

Br J Clin Pharmacol. 2013 Aug;76(2):277-91. doi: 10.1111/bcp.12036. Review.

3.

Biologic therapy in asthma: entering the new age of personalized medicine.

Fajt ML, Wenzel SE.

J Asthma. 2014 Sep;51(7):669-76. doi: 10.3109/02770903.2014.910221. Epub 2014 May 13. Review.

PMID:
24712500
4.

Immunomodulatory and biologic therapies for severe refractory asthma.

Polosa R, Morjaria J.

Respir Med. 2008 Nov;102(11):1499-510. doi: 10.1016/j.rmed.2008.09.006. Review.

5.

Developmental current and future therapy for severe asthma.

Nakamura Y.

Inflamm Allergy Drug Targets. 2013 Feb;12(1):54-60. Review.

PMID:
23062274
6.

Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.

Levine SJ, Wenzel SE.

Ann Intern Med. 2010 Feb 16;152(4):232-7. doi: 10.7326/0003-4819-152-4-201002160-00008. Review.

7.

Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.

Caruso M, Crisafulli E, Demma S, Holgate S, Polosa R.

Expert Opin Biol Ther. 2013 Mar;13(3):393-402. doi: 10.1517/14712598.2013.743989. Epub 2013 Jan 7. Review.

PMID:
23289846
8.

Biologic targeted therapy in allergic asthma.

Bice JB, Leechawengwongs E, Montanaro A.

Ann Allergy Asthma Immunol. 2014 Feb;112(2):108-15. doi: 10.1016/j.anai.2013.12.013. Review.

PMID:
24468249
9.

Monoclonal antibodies for chronic refractory asthma and pipeline developments.

Polosa R, Casale T.

Drug Discov Today. 2012 Jun;17(11-12):591-9. doi: 10.1016/j.drudis.2012.01.012. Epub 2012 Jan 25. Review.

PMID:
22306350
10.

An update on emerging drugs for asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2012 Mar;17(1):37-42. doi: 10.1517/14728214.2012.657625. Epub 2012 Jan 31. Review.

PMID:
22292562
11.

Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?

De Ferrari L, Chiappori A, Bagnasco D, Riccio AM, Passalacqua G, Canonica GW.

Expert Rev Respir Med. 2016;10(1):29-38. doi: 10.1586/17476348.2016.1111763. Epub 2015 Nov 13. Review.

PMID:
26566089
12.

Experimental approaches towards allergic asthma therapy-murine asthma models.

Wegmann M, Hauber HP.

Recent Pat Inflamm Allergy Drug Discov. 2010 Jan;4(1):37-53. Review.

PMID:
19891606
13.

A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.

D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.

Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. Review.

PMID:
19075985
14.

Asthma phenotypes and endotypes: a personalized approach to treatment.

Skloot GS.

Curr Opin Pulm Med. 2016 Jan;22(1):3-9. doi: 10.1097/MCP.0000000000000225. Review.

PMID:
26574717
15.

IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies.

Ingram JL, Kraft M.

J Allergy Clin Immunol. 2012 Oct;130(4):829-42; quiz 843-4. doi: 10.1016/j.jaci.2012.06.034. Epub 2012 Aug 27. Review.

PMID:
22951057
16.

Monoclonal antibodies for the treatment of severe asthma.

Clienti S, Morjaria JB, Basile E, Polosa R.

Curr Allergy Asthma Rep. 2011 Jun;11(3):253-60. doi: 10.1007/s11882-011-0184-9. Review.

PMID:
21360131
17.

Emerging drugs for asthma.

Quirce S, Bobolea I, Barranco P.

Expert Opin Emerg Drugs. 2012 Jun;17(2):219-37. doi: 10.1517/14728214.2012.683410. Epub 2012 May 21. Review.

PMID:
22607631
18.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, Liu Z, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. Review.

19.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
20.

[Imbalanced T cell-specific transcription factors T-bet and GATA-3 contributes to type 2 T helper cell polarization in asthmatic patients].

Liu CT, Wang G, Luo FM, Wang ZL, Liu R, Wang CL.

Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jun;27(6):398-402. Chinese.

PMID:
15256090

Supplemental Content

Support Center